Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solitary Fibrous Tumors × eribulin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 52 Triple Negative Breast Neoplasms 13 Sarcoma 6 Neoplasm Metastasis 5 Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Prostatic Neoplasms 2 Inflammatory Breast Neoplasms 2 HER2-negative Breast Cancer 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Sarcoma, Ewing 1 Salivary Gland Neoplasms 1 Rhabdomyosarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Liposarcoma 1 Leiomyosarcoma 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1

Interventions

pazopanib 1 eribulin 1 Trabectedin 1 Doxorubicin 1 Dasatinib 1 Dacarbazine 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03840772 2024-09-20

ERASING

Italian Sarcoma Group

Phase 2 Completed

Sarcoma, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡